Updates are available Correction dated 2020-09-11
Click to view Correction: https://doi.org/10.1038/s41467-020-18621-3
-
Authors
Woodcock, Hannah V.
Eley, Jessica D.
Guillotin, Delphine
Platé, Manuela https://orcid.org/0000-0002-9957-0681
Nanthakumar, Carmel B.
Martufi, Matteo
Peace, Simon
Joberty, Gerard
Poeckel, Daniel
Good, Robert B.
Taylor, Adam R.
Zinn, Nico
Redding, Matthew
Forty, Ellen J.
Hynds, Robert E. https://orcid.org/0000-0002-2170-8791
Swanton, Charles
Karsdal, Morten
Maher, Toby M.
Fisher, Andrew
Bergamini, Giovanna
Marshall, Richard P.
Blanchard, Andy D.
Mercer, Paul F.
Chambers, Rachel C. https://orcid.org/0000-0003-1370-9417
- License Information
-
More Information
Article History
Received: 20 December 2017
Accepted: 29 November 2018
First Online: 2 January 2019
Change Date: 11 September 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: This work was part-funded by a collaborative framework agreement awarded to R.C.C. by GlaxoSmithKline. In terms of potential conflict of interest, the following authors: C.B.N., M.M., S.P., G.J., D.P., R.B.G., A.R.T., G.B., A.D.B., N.Z., and R.P.M. were employees of GlaxoSmithKline which has R&D programs for IPF at the time of writing. M.K. is an employee of Nordic Biosciences with a commercial interest in proprietary assay development for biomarker discovery. T.M.M. has no declarations directly related to this manuscript. He has, however, received industry-academic research funding from GlaxoSmithKline R&D, UCB, and Novartis and has received consultancy or speakers fees from Pellis, Astra Zeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, Galapagos, GlaxoSmithKline R&D, ProMetic, Roche (and previously InterMune), Sanofi-Aventis, and UCB. A.J.F. has no declarations directly related to this manuscript. His institution has received industry-academic research funding from GlaxoSmithKline R&D, Genentech, Pfizer and Nuformix. His institution has received consultancy fees from Mallinckrodt Pharmaceuticals. All remaining authors declare no competing interests. All data presented have been recorded in full compliance with GSK data integrity.
